['Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.12) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.12). Leap Therapeutics had a negative net margin of 2,161.80% and a negative return on equity of 77.18%. The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.38 million. ', '\n\n\n\n\n\n                 Several brokerages recently commented on LPTX. Zacks Investment Research upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Thursday, August 5th. Piper Sandler cut their price target on shares of Leap Therapeutics from $6.00 to $4.00 and set an “overweight” rating on the stock in a research note on Monday, May 17th.', 'Shares of LPTX opened at $1.68 on Friday. The firm has a fifty day moving average price of $1.58. Leap Therapeutics has a twelve month low of $1.33 and a twelve month high of $3.24. The firm has a market cap of $100.25 million, a price-to-earnings ratio of -4.00 and a beta of 1.21. ', 'A number of large investors have recently made changes to their positions in the stock. FMR LLC raised its stake in  Leap Therapeutics by 63.3% during the 1st quarter. FMR LLC now owns 1,563,124 shares of the company’s stock worth $2,923,000 after acquiring an additional 606,000 shares in the last quarter.  Opaleye Management Inc. increased its stake in  Leap Therapeutics by 39.1% in the second quarter. Opaleye Management Inc. now owns 540,000 shares of the company’s stock valued at $886,000 after purchasing an additional 151,900 shares during the period.  Geode Capital Management LLC increased its stake in  Leap Therapeutics by 5.1% in the second quarter. Geode Capital Management LLC now owns 367,321 shares of the company’s stock valued at $602,000 after purchasing an additional 17,880 shares during the period.  Silverarc Capital Management LLC increased its stake in  Leap Therapeutics by 9.1% in the first quarter. Silverarc Capital Management LLC now owns 300,000 shares of the company’s stock valued at $570,000 after purchasing an additional 25,000 shares during the period.  Finally, BlackRock Inc. increased its stake in  Leap Therapeutics by 6.4% in the first quarter. BlackRock Inc. now owns 211,968 shares of the company’s stock valued at $403,000 after purchasing an additional 12,804 shares during the period. Hedge funds and other institutional investors own  36.91% of the company’s stock. ', 'Leap Therapeutics Company Profile', 'Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer.', 'See Also: 52 Week Highs\n', 'Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)', 'For more information about research offerings from Zacks Investment Research, visit Zacks.com', '', "Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.", 'MKM Partners Increases Flora Growth (NASDAQ:FLGC) Price Target to $11.50']


